AGL Share PerformanceMore
|52 week high||80.00 15/06/17|
|52 week low||44.00 30/03/17|
|52 week change||6.50 (10.40%)|
|4 week volume||5,107,892 29/05/17|
Media for (AGL)
Latest News« previous» nextMore
15/06/2017 - 08:46 StockMarketWire
London shares opened lower as a lengthy list of ex-dividend stocks undoubtedly weighed and as investors looked to the mid...
15/06/2017 - 07:00 RNS
RNS Number: 1286I Angle PLC 15 June 2017 For immediate release 15 June 2017 ANGLE plc ("the Company") PARSORTIX BREAKTHROUGH DELIVERS RARE BLOOD CELL DISCOVERY IN PROSTATE CANCER Barts Cancer Institute study finds rare type of cell in cancer patient blood linked to survival Use of Parsortix identifies patients that are 10 times m...
05/06/2017 - 07:43 StockMarketWire
ANGLE has announced that researchers have presented successful results from their work using the company's Parsortix ...
05/06/2017 - 07:00 RNS
RNS Number: 0859H Angle PLC 05 June 2017 For immediate release 5 June 2017 ANGLE plc ("the Company") SUCCESS WITH PARSORTIX IN COLORECTAL CANCER Clinically relevant results presented at ASCO 2017 cancer conference Demonstrates use of the Parsortix system to predict resistance to cancer drugs ANGLE plc (AIM:AGL OTCQX:ANPCY), the s...
03/05/2017 - 07:00 RNS
RNS Number: 9768D Angle PLC 03 May 2017 For immediate release 3 May 2017 ANGLE plc ("the Company") BUSINESS UPDATE HIGHLIGHTS PROGRESS WITH PARSORTIX LIQUID BIOPSY Ovarian cancer clinical studies progressing well with patient enrolment completed. Headline data on target for reporting this quarter MD Anderson Cancer Center signed...
04/04/2017 - 07:00 RNS
RNS Number: 4527B Angle PLC 04 April 2017 For immediate release 4 April 2017 ANGLE plc ("the Company") Holding(s) in Company The Company has been informed by Lombard Odier Investment Managers group ("Lombard") that, following its recent acquisition of Henderson Volantis from Henderson Global plc ("Henderson"), Lombard has acquired ordina...
03/04/2017 - 07:00 RNS
RNS Number: 2731B Angle PLC 03 April 2017 For immediate release 3 April 2017 ANGLE plc ("the Company") PARSORTIX ENABLES GENE EXPRESSION ANALYSIS IN HEAD AND NECK CANCER Customer presents clinically relevant results at AACR 2017 with Parsortix where alternative approaches have failed University of Athens, Attikon University H...
30/03/2017 - 07:00 RNS
RNS Number: 9546A Angle PLC 30 March 2017 For immediate release 30 March 2017 ANGLE plc ("the Company") POTENTIAL FOR PREDICTION OF METASTASIS IN PROSTATE CANCER Barts Cancer Institute present new findings at World CDx Europe 2017 conference in London ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is...
|Dividend yield||0 %|
Equity Research (AGL)
Yesterday Angle announced that researchers from Queen Mary University of London's Barts Cancer Institute (BCI) published new data further supporting Angle’s Parsortix system for use in prostate...
Toople* (TOOP.L) 3.25p £3.25m The provider of bespoke telecom services to UK SMEs, announced that it received a strong response from investors pursuant to Initial C l o s i n g o f t h e...
InnovaDerma* (IDP.L) 133.5p £15.81m The UK developer of life sciences, beauty and personal care products today provided an update on trading and announces it has secured new e-tailer distribution...
- 1 of 7
Latest discussion posts More
“Whereas the Daily Mail article seemed to relate to the RNS and was very encouraging,; this Telegraph article headed "Blood test could revolutionise prostate cancer treatment" ...”▼
“I posted the question the day before the News was announced and after 2 days of strong gains. Now its obvious.”▼
Codes & Symbols
|Symbols||AGL, LSE:AGL, AGL.L, AGL:LN, LON:AGL, XLON:AGL|